Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia

Annals of Hematology

Volumn 93, Issue 12, 2014, Pages 2011-2018

  De Astis, Enrico ^a   Clavio, Marino ^a   Raiola, Anna Maria ^a   Ghiso, Anna ^a   Guolo, Fabio ^a   Minetto, Paola ^a   Galaverna, Federica ^a   Miglino, Maurizio ^a   Di Grazia, Carmen ^a   Ballerini, Filippo ^a   Marani, Carlo ^a   Pastori, Giordana ^a   Mitscheunig, Laura ^a   Cruciani, Fabio ^a   Lovera, Davide ^a   Varaldo, Riccardo ^a   Ghiggi, Chiara ^a   Lemoli, Roberto Massimo ^a   Bacigalupo, Andrea ^a   Gobbi, Marco ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

ALL; AML; Cytarabine; Fludarabine; HSCT; Liposomal daunorubicin; Relapsed refractory acute leukemias; Stem cell transplant

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; LIPOSOME; VIDARABINE;

ADOLESCENT; ADULT; AGED; ANALOGS AND DERIVATIVES; BLOOD COMPONENT THERAPY; CHEMICALLY INDUCED; CONSOLIDATION CHEMOTHERAPY; DIARRHEA; DRUG ADMINISTRATION; DRUG SCREENING; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; KAPLAN MEIER METHOD; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROPORTIONAL HAZARDS MODEL; REMISSION; RETROSPECTIVE STUDY; SALVAGE THERAPY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD COMPONENT TRANSFUSION; COMBINED MODALITY THERAPY; CONSOLIDATION CHEMOTHERAPY; CYTARABINE; DAUNORUBICIN; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; LIPOSOMES; MALE; MIDDLE AGED; NEUTROPENIA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; VIDARABINE; YOUNG ADULT;

EID: 84922218725     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2143-8     Document Type: Article

References (25)

1. Fielding AK, Richards SM, Chopra R et al (2007) Medical Research Council of the United Kingdom Adult ALL Working Party. Outcome of 609 adults after relapse of acute lymphoblastic leukaemia (ALL): an MRC UKALL12/ECOG 2993 study. Blood 109:944–950
2. Kantarjian HM, Thomas D, Ravandi F, Faderl S, Garcia-Manero G, Shan J, Pierce S, Cortes J, O'Brien S (2010) Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission. Leuk Lymphoma 51(3):475–480
3. Tavernier E, Boiron JM, Huguet F, GET-LALA Group; Swiss Group for Clinical Cancer Research SAKK; Australasian Leukaemia and Lymphoma Group et al (2007) Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 21:1907–1914
4. O'Brien S, Thomas D, Ravandi F, Faderl S, Cortes J, Borthakur G, Pierce S, Garcia-Manero G, Kantarjian HM (2008) Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 113(11):3186–3191
5. Litzow MR, Othus M, Cripe LD, Gore SD, Lazarus HM, Lee SJ, Bennett JM, Paietta EM, Dewald GW, Rowe JM, Tallman MS, Eastern Cooperative Oncology Group LeukemiaCommittee (2010) Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group. Br J Haematol 148(2):217–225
6. Jeha S, Gandhi V, Chan KW et al (2004) Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 103:784–789
7. DeAngelo DJ, Yu D, Johnson JL et al (2007) Nelarabine induces complete remissions in adults with relapsed or refractory T lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood 109:5136–5142
8. Ottmann OG, Druker BJ, Sawyers CL et al (2002) A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100:1965–1971
9. Ottmann O, Dombret H, Martinelli G et al (2007) Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 110:2309–2315
10. Tischer J, Stemmler HJ, Engel N, Hubmann M, Fritsch S, Prevalsek D, Schulz C, Zoellner AK, Bücklein V, Hill W, Ledderose G, Hausmann A (2013) Feasibility of clofarabine cytoreduction followed by haploidentical hematopoietic stem cell transplantation in patients with relapsed or refractory advanced acute leukemia. Ann Hematol 92(10):1379–1388
11. Pilorge S, Rigaudeau S, Rabian F, Sarkozy C, Taksin AL, Farhat H, Merabet F, Ghez S, Raggueneau V, Terré C, Garcia I, Renneville A, Preudhomme C, Castaigne S, Rousselot P (2014) Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse. Am J Hematol 89(4):399–403
12. Tsunemine H, Akasaka H, Sakane EI, Ito K, Kodaka T, Takahashi T (2014) Successful repeated treatment of acute myeloid leukemia in early relapse with gemtuzumab ozogamicin alone. Int J Hematol 99(2):193–197
13. Pierri I, Miglino M, Gatto S, Venturino C, Quintino S, Beltrami G, Lanino E, Clavio M, Canepa L, Gobbi M (2000) Combination of liposomal daunorubicin (Daunoxome), fludarabine and cytarabine as salvage therapy in relapsed and refractory acute leukemia. Blood 96(suppl 2):215b
14. Clavio M, Venturino C, Pierri I, Garrone A, Miglino M, Canepa L, Balleari E, Balocco M, Michelis GL, Ballerini F, Gobbi M (2004) Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. Ann Hematol 83(11):696–703
15. Candoni A, Michelutti A, Simeone E, Damiani D, Baccarani M, Fanin R (2006) Efficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukaemia despite expression of multidrug resistance-related proteins. Eur J Haematol 77(4):293–299
16. Cortes J, Estey E, O'Brien S, Giles F, Shen Y, Koller C, Beran M, Thomas D, Keating M, Kantarjian H (2001) High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia. Cancer 92:7–14
17. Russo D, Piccaluga PP, Michieli M, Michelutti T, Visani G, Gugliotta L, Bonini A, Pierri I, Gobbi M, Tiribelli M, Fanin R, Piccolrovazzi S, Baccarani M (2002) Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia. Ann Haematol 81:462–466
18. Baccarani M, Russo D, Fanin R, Michieli M (2000) Liposomal daunorubicin (Daunoxome) in the treatment of acute lymphocytic leukemia (ALL). Blood 96(suppl 1):720a, abtr. 3110
19. Ermacora A, Michieli M, Pea F, Visani G, Bucalossi A, Russo D (2000) Liposome encapsulated daunorubicin (Daunoxome) for acute leukemia. Haematologica 85:324–325
20. Piccaluga PP, Visani G, Martinelli G, Isidori A, Malagola M, Rondoni M, Baccarani M, Tura S (2010) Liposomal daunorubicin (DaunoXome) for treatment of relapsed meningeal acute myeloid leukemia. Leukemia 16(9):1880–1881
21. Raiola AM, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, Bregante S, Van Lint MT, Geroldi S, Luchetti S, Ballerini F, Miglino M, Bacigalupo A, Varaldo R (2013) Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies aftermyeloablative conditioning. Biol Blood Marrow Transplant 19(1):117–122
22. Frassoni F, Gualandi F, Podestà M, Raiola AM, Ibatici A, Piaggio G, Sessarego M, Sessarego N, Gobbi M, Sacchi N, Labopin M, Bacigalupo A (2008) Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol 9(9):831–839. doi:10.1016/S1470-2045(08)70180-3
23. Sanz J, Boluda JC, Martín C, González M, Ferrá C, Serrano D, de Heredia CD, Barrenetxea C, Martinez AM, Solano C, Sanz MA, Sanz GF, Grupo Español de Trasplante Hematopoyético y Terapia Celular (2012) Single-unit umbilical cord blood transplantation from unrelated donors in patients with haematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. Bone Marrow Transplant 47(10):1287–1293
24. Michieli M, Damiani D, Ermacora A, Masolini P, Michielutti A, Michelutti T, Russo D, Pea F, Baccarani M (1999) Liposomal-encapsulated daunorubicin for Pgp-related multidrug resistance. Br J Haematol 106:92–99
25. Camera A, Rinaldi CR, Palmieri S, Cantore N, Mele G, Mettivier V, Miraglia E, Mastrullo L, Grimaldi F, Luciano L, Guerriero A, Rotoli B, Ferrara F (2009) Sequentialcontinuous infusion of fludarabine and cytarabine associated with liposomal daunorubicin (DaunoXome) (FLAD) in primary refractory or relapsed adult acute. myeloid leukemia patients. Ann Hematol 88(2):151–158